Top

Published in:

Open Access 01-06-2019 | Actinic Keratosis | Review

Review of Clinical Evidence over 10 Years on Prevention and Treatment of a Film-Forming Medical Device Containing Photolyase in the Management of Field Cancerization in Actinic Keratosis

Authors: Susana Puig, Corinne Granger, Aurora Garre, Carles Trullàs, Onofre Sanmartin, Giuseppe Argenziano

Published in: Dermatology and Therapy | Issue 2/2019

Abstract

Actinic keratosis (AK) is a common pathology that afflicts sun-exposed areas of the skin. It predominantly affects older and fair-skinned individuals suggesting an accumulative damage attributable to chronic sun exposure. The prevalence of AK has risen in the past decades and is expected to continue to rise. Apart from visible hyperkeratotic, hyperplastic lesions, AK is also associated with the presence of subclinical lesions adjacent to tumor tissue, which has led to the use of the concept “cancerization field”. Although lesion- and field-targeting treatments are currently available, many are associated with local side effects and recurrence of new lesions. This review provides information on AK pathophysiology and treatment options and summarizes the available clinical evidence supporting the use of Eryfotona AK-NMSC, a film-forming medical device with SPF 100+ containing the DNA repair enzyme photolyase, for managing AK, based on the analysis of the results of 228 patients treated with the product.

Funding

ISDIN funded the Article Processing Charges.

Available only for authorised users

Stockfleth E, Kerl H, Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16(6):599–606.PubMed

Krutmann J, Berking C, Berneburg M, Diepgen TL, Dirschka T, Szeimies M. New strategies in the prevention of actinic keratosis: a critical review. Skin Pharmacol Physiol. 2015;28(6):281–9.PubMedCrossRef

Laino L, Elia F, Desiderio F, et al. The efficacy of a photolyase-based device on the cancerization field: a clinical and thermographic study. J Exp Clin Cancer Res. 2015;34(1):84.PubMedPubMedCentralCrossRef

Naldi L, Chatenoud L, Piccitto R, et al. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003–2004. Arch Dermatol. 2006;142(6):722–6.PubMedCrossRef

Ceilley RI, Jorizzo JL. Current issues in the management of actinic keratosis. J Am Acad Dermatol. 2013;68(1 Suppl 1):S28–38.PubMedCrossRef

Roewert-Huber J, Stockfleth E, Kerl H. Pathology and pathobiology of actinic (solar) keratosis—an update. Br J Dermatol. 2007;157(Suppl 2):18–20.PubMedCrossRef

Dréno B, Amici JM, Basset-Seguin N, et al. Management of actinic keratosis: a practical report and treatment algorithm from AKTeam™ expert clinicians. J Eur Acad Dermatol Venereol. 2014;28(9):1141–9.PubMedCrossRef

Roewert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol. 2007;156(Suppl 3):8–12.CrossRef

Werner RN, Stockfleth E, Connolly SM, et al. Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis—International League of Dermatological Societies in cooperation with the European Dermatology Forum—Short version. J Eur Acad Dermatol Venereol. 2015;29(11):2069–79.PubMedCrossRef

10.

Rossi R, Mori M, Lotti T. Actinic keratosis. Int J Dermatol. 2007;46(9):895–904.PubMedCrossRef

11.

Yanofsky VR, Mercer SE, Phelps RG. Histopathological variants of cutaneous squamous cell carcinoma: a review. J Skin Cancer. 2011;2011:210813.PubMedCrossRef

12.

Trakatelli M, Ulrich C, del Marmol V, Euvrard S, Stockfleth E, Abeni D. Epidemiology of nonmelanoma skin cancer (NMSC) in Europe: accurate and comparable data are needed for effective public health monitoring and interventions. Br J Dermatol. 2007;156(Suppl 3):1–7.PubMedCrossRef

13.

Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22(3):189–96.PubMedCrossRef

14.

Lalji A, Khiroya N, Lalji M. Actinic keratosis and squamous cell carcinoma. Clin Res Dermatol Open. 2014;1(1):1–3.

15.

Emre S. Actinic keratosis and field cancerization. World J Dermatol. 2016;5(2):115–24.CrossRef

16.

Green A, Battistutta D. Incidence and determinants of skin cancer in a high-risk Australian population. Int J Cancer. 1990;46(3):356–61.PubMedCrossRef

17.

Schaefer I, Augustin M, Spehr C, Reusch M, Kornek T. Prevalence and risk factors of actinic keratoses in Germany—analysis of multisource data. J Eur Acad Dermatol Venereol. 2014;28(3):309–13.PubMedCrossRef

18.

Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol. 2000;142(6):1154–9.PubMedCrossRef

19.

Ferrándiz C, Plazas MJ, Sabaté M, Palomino R, EPIQA Study Group. Prevalence of actinic keratosis among dermatology outpatients in Spain. Actas Dermosifiliogr. 2016;107(8):674–80.PubMedCrossRef

20.

Flohil SC, van der Leest RJ, Dowlatshahi EA, Hofman A, de Vries E, Nijsten T. Prevalence of actinic keratosis and its risk factors in the general population: the Rotterdam Study. J Invest Dermatol. 2013;133(8):1971–8.PubMedCrossRef

21.

Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000;42(1 Suppl 2):4–7.PubMedCrossRef

22.

Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998;139(6):1033–9.PubMedCrossRef

23.

Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol. 2000;115(2):273–7.PubMedCrossRef

24.

Fernández-Figueras MT, Carrato C, Sáenz X, et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29(5):991–7.PubMedCrossRef

25.

Premi S, Wallisch S, Mano CM, et al. Photochemistry. Chemiexcitation of melanin derivatives induces DNA photoproducts long after UV exposure. Science. 2015;347(6224):842–7.PubMedPubMedCentralCrossRef

26.

Torezan LA, Festa-Neto C. Cutaneous field cancerization: clinical, histopathological and therapeutic aspects. An Bras Dermatol. 2013;88(5):775–86.PubMedPubMedCentralCrossRef

27.

Szeimies RM, Torezan L, Niwa A, et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol. 2012;167(1):150–9.PubMedCrossRef

28.

Chai H, Brown RE. Field effect in cancer-an update. Ann Clin Lab Sci. 2009;39(4):331–7.PubMed

29.

Malvehy J. A new vision of actinic keratosis beyond visible clinical lesions. J Eur Acad Dermatol Venereol. 2015;29(Suppl 1):3–8.PubMedCrossRef

30.

Malvehy J, Roldán-Marín R, Iglesias-García P, Díaz A, Puig S. Monitoring treatment of field cancerisation with 3% diclofenac sodium 2.5% hyaluronic acid by reflectance confocal microscopy: a histologic correlation. Acta Derm Venereol. 2015;95(1):45–50.PubMedCrossRef

31.

Puig S, Puig-Butillé JA, Díaz MA, Trullas C, Malvehy J. Field cancerisation improvement with topical application of a film-forming medical device containing photolyase and UV filters in patients with actinic keratosis, a pilot study. J Clin Exp Dermatol Res. 2014;5:3.

32.

Stockfleth E. Actinic keratosis and field cancerisation. Eur J Dermatol. 2011;21(Suppl 1):3–12.

33.

Zalaudek I, Piana S, Moscarella E, et al. Morphologic grading and treatment of facial actinic keratosis. Clin Dermatol. 2014;32(1):80–7.PubMedCrossRef

34.

Rossi R, Calzavara-Pinton PG, Giannetti A, et al. Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol. 2009;144(6):713–23.PubMed

35.

Bonerandi JJ, Beauvillain C, Caquant L, et al. Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions. J Eur Acad Dermatol Venereol. 2011;25(Suppl 5):1–51.PubMedCrossRef

36.

Stockfleth E, Ferrandiz C, Grob JJ, et al. Development of a treatment algorithm for actinic keratoses: a European consensus. Eur J Dermatol. 2008;18(6):651–9.PubMed

37.

Nashan D, Meiss F, Müller M. Therapeutic strategies for actinic keratoses—a systematic review. Eur J Dermatol. 2013;23(1):14–32.PubMed

38.

de Berker D, McGregor JM, Hughes BR, British Association of Dermatologists Therapy. Guidelines and Audit Subcommittee Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156(2):222–30.PubMedCrossRef

39.

Point K. Clinical Practice Guide: Basal cell carcinoma, squamous cell carcinoma (and related lesions)—a guide to clinical management in Australia. Sydney: Cancer Council Australia and Australian Cancer Network; 2008.

40.

Drake LA, Ceilley RI, Cornelison RL, et al. Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol. 1995;32(1):95–8.PubMedCrossRef

41.

Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(Suppl 2):34–40.PubMedCrossRef

42.

Puviani M, Galloni C, Marhetti S, et al. Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial. Curr Med Res Opin. 2017;33(7):1255–9.PubMedCrossRef

43.

Ceccoli J, Rosales N, Tsimis J, Yarosh DB. Encapsulation of the UV-DNA repair enzyme T4 endonuclease V in liposomes and delivery to human cells. J Invest Dermatol. 1989;93(2):190–4.PubMedCrossRef

44.

Yarosh D, Bucana C, Cox P, Alas L, Kibitel J, Kripke M. Localization of liposomes containing a DNA repair enzyme in murine skin. J Invest Dermatol. 1994;103(4):461–8.PubMedCrossRef

45.

Stege H, Roza L, Vink AA, et al. Enzyme plus light therapy to repair DNA damage in ultraviolet-B-irradiated human skin. Proc Natl Acad Sci USA. 2000;97:1790–5.PubMedCrossRef

46.

Stege H. Effect of xenogenic repair enzymes on photoimmunology and photocarcinogenesis. J Photochem Photobiol B. 2001;65:105–8.PubMedCrossRef

47.

Puviani M, Barcella A, Milani M. Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer. G Ital Dermatol Venereol. 2013;148(6):693–8.PubMed

48.

Puviani M, Milani M. A Pilot, prospective, open-label study on the effects of a topical photorepair and photoprotection film-forming medical device in patients with actinic keratoses evaluated by means of skin analysis camera antera 3D. J Clin Exp Dermatol Res. 2015;6(263):2.

49.

Puig-Butillé JA, Malvehy J, Potrony M, et al. Role of CPI-17 in restoring skin homoeostasis in cutaneous field of cancerization: effects of topical application of a film-forming medical device containing photolyase and UV filters. Exp Dermatol. 2013;22(7):494–6.PubMedPubMedCentralCrossRef

50.

Rstom SA, Abdalla BM, Rezze GG, Paschoal FM. Evaluation of the effects of a cream containing liposomeencapsulated photo lyase and SPF 100 sunscreen on facial actinic keratosis: clinical, dermoscopic, and confocal microscopy based analysis. Surg Cosmet Dermatol. 2014;6(3):226–31.

51.

Giustini S, Miraglia E, Berardesca E, Milani M, Calvieri S. Preventive long-term effects of a topical film-forming medical device with ultra-high UV protection filters and dna repair enzyme in xeroderma pigmentosum: a retrospective study of eight cases. Case Rep Dermatol. 2014;6(3):222–6.PubMedPubMedCentralCrossRef

52.

Navarrete-Dechent C, Molgó M. The use of a sunscreen containing DNA photolyase in the treatment of patients with field cancerization and multiple actinic keratosis: a case series. Dermatol Online J. 2017;23(1):1–3.

53.

Moscarella E, Argenziano G, Longo C, Aladren S. Management of cancerization field with a medical device containing photolyase: a randomized, double-blind, parallel-group pilot study. J Eur Acad Dermatol Venereol. 2017;31(9):e401–3.PubMedCrossRef

54.

Eibenschutz L, Silipo V, De Simone P, et al. A 9-month, randomized, assessor-blinded, parallel-group study to evaluate clinical effects of film-forming medical devices containing photolyase and sun filters in the treatment of field cancerization compared with sunscreen in patients after successful photodynamic therapy for actinic keratosis. Br J Dermatol. 2016;175(6):1391–3.PubMedCrossRef

55.

Vaño-Galván S, Jiménez N, Grillo E, Ballester A. An observational study on the effectiveness and safety of the combination of a topical product containing photolyase and cryotherapy in patients with actinic keratoses in clinical practice (article in Spanish). Piel. 2016;31(8):532–6.CrossRef

56.

Berardesca E, Bertona M, Altabas K, Altabas V, Emanuele E. Reduced ultraviolet-induced DNA damage and apoptosis in human skin with topical application of a photolyase-containing DNA repair enzyme cream: clues to skin cancer prevention. Mol Med Rep. 2012;5:570–4.PubMed

Title: Review of Clinical Evidence over 10 Years on Prevention and Treatment of a Film-Forming Medical Device Containing Photolyase in the Management of Field Cancerization in Actinic Keratosis
Authors: Susana Puig
Corinne Granger
Aurora Garre
Carles Trullàs
Onofre Sanmartin
Giuseppe Argenziano
Publication date: 01-06-2019
Publisher: Springer Healthcare
Keywords: Actinic Keratosis
Photodynamic Therapy
Cryotherapy
Cryotherapy
Skin Cancer
Published in: Dermatology and Therapy / Issue 2/2019
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI: https://doi.org/10.1007/s13555-019-0294-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Review of Clinical Evidence over 10 Years on Prevention and Treatment of a Film-Forming Medical Device Containing Photolyase in the Management of Field Cancerization in Actinic Keratosis

Abstract

Funding

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Funding

Please log in to get access to this content

Other articles of this Issue 2/2019

Understanding the Burden of Atopic Dermatitis in Africa and the Middle East

Efficacy Assessment of a Topically Applied Nitric–Zinc Complex Solution for the Treatment of External Ano-genital Warts in 100 Patients

A National Survey of Medical Oncologist’s Opinions and Perceptions for Managing Rash Among mCRC Patients Treated with Panitumumab

The Scar Bane, Without the Pain: A New Approach in the Treatment of Elevated Scars: Thermomechanical Delivery of Topical Triamcinolone Acetonide and 5-Fluorouracil

Correction to: Efficacy and Tolerability of a Medical Device Repairing Emollient Cream Associated with a Topical Corticosteroid in Adults with Atopic Dermatitis: An Open-label, Intra-individual Randomized Controlled Study

Intralesional Methotrexate for the Treatment of Keratoacanthoma: The Neapolitan Experience

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page